Adiposs Raises CHF 4 million in Series A
Share this article
Adiposs SA, a Geneva-based clinical-stage Swiss life sciences company announced the successful closing of a CHF 4 million Series A financing round. The round was syndicated by Swiss and Taiwanese VC firms, European family offices and high-net-worth individual investors.
Adiposs is pioneering the development of the first imaging product for brown fat designed to predict response to cancer therapy and enable personalized cancer treatment at scale. The financing will be used for proof-of-principle clinical development of Adiposs’ first-in-class asset, ImageBAT®, a novel contrast agent designed for non-invasive CT imaging of brown fat in cancer patients, which cannot be reliably achieved today. This milestone marks a significant step toward addressing a critical unmet medical need in oncology: identifying non-responding cancer patients early.
“We are thrilled to have the support of such a distinguished group of investors who share our mission for improving cancer patient outcomes globally,” said Andrej Babic, Chief Executive Officer of Adiposs SA. “This financing enables us to move rapidly into further clinical development and generate the proof-of-principle data needed to unlock the full potential of our
innovative technology.”
With the completion of its Series A financing, the company is further strengthening its Board of Directors to support its next phase of growth. “We are delighted to welcome Peter Lichtlen, MD, and Johnny Chen, MBA, to the Board of Directors of Adiposs SA,” said Reinhard K. Stary, Chairman of the Board. “Peter brings a remarkable entrepreneurial track record in biotech and oncology, having achieved three successful exits. Johnny, a former Partner at KPMG and PwC in Asia and an accomplished venture capital and private equity investor, will further enhance Adiposs’ Board. Their combined expertise will be invaluable as we advance our clinical development and expand our business and fundraising efforts globally.”
Adiposs’ proprietary technology leverages standard-of-care oncology CT scans widely available in hospitals worldwide, positioning the company at the forefront of scalable innovation in oncology. The company has received regulatory authorization to initiate the IBT-002 clinical and dosed the first subjects in June 2025. Top line data are expected in Q1 2026.
➡️ Source: Adiposs | 📸 L to R: Duc Tran, Chief Development Officer, Hervé Porchet, Chief Medical Officer, Nathalie Stransky Chief Technology Officer and Co-founder, Andrej Babic, Chief Executive Officer and Co-founder of Adiposs. © Adiposs